

2021 Cuba Tumor Markers Market Assessment- Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, Lymphokines-Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

<https://marketpublishers.com/r/288A36BC30BDEN.html>

Date: March 2021

Pages: 535

Price: US\$ 3,500.00 (Single User License)

ID: 288A36BC30BDEN

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric

population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 535 pages and 70 tables

Contents

I. INTRODUCTION

II. MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Cancer Diagnostic Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT

- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Cancer Diagnostics
- 27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg
 - Sis
 - Src and others
- 28. Polypeptide Growth Factors
 - Basic Fibroblast Growth Factor
 - Beta-TGF
 - Cachectin (TNT)
 - Calmodulin
 - ECFR
 - Nerve Growth Factor (NGF)
 - Epidermal Growth Factor (EGF)
 - Ornithine Decarboxylase
 - Transferrin
 - Transforming Growth Factor-Alpha
- 29. Ectopic Hormones
- 30. Colony Stimulating Factors
- 31. Lymphokines

Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Cancer Diagnostics
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA
CA 72-4/TAG-72
CA
CA-242
CA-549
CAM
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH

(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)

Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen and others

VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS

IX. CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence

6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies

X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

XI. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic
Leica Biosystems
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako and others.

I would like to order

Product name: 2021 Cuba Tumor Markers Market Assessment-Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, Lymphokines-Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/288A36BC30BDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/288A36BC30BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970